Overview


Cancer is a condition that causes uncontrolled cell growth. There are approximately 100 types of cancer. Each type is classified according to the type of cell it affects. Breast cancer is most common in women. However, it is uncommon in men. Breast cancer is a leading cause of death in elderly women. The most common forms of breast cancer include ductal carcinomas in situ (DCIS), and lobular carcinoma. DCIS, also known intraductal carcinoma, is found in the linings of the milk ducts. Milk ducts are thin tubes that carry milk from the breast lobules to the nipple. The lobules, or milk glands, are where lobule carcinoma is found. Breast cancer is most commonly diagnosed as invasive ductal carcinoma. It begins in the milk duct of breast and ruptures through the wall. The breast fatty tissue then grows from it. It can spread to other areas of the body via bloodstream.

Breast cancer therapy is the treatment or management using therapeutic approach and drugs, such as chemotherapy, hormonal therapy, targeted therapy, and other therapeutics. These therapies reduce the growth and multiplication cancerous cells through disruption of certain proteins or DNA. The most common drugs used in breast cancer treatment are HER2 inhibitors and mitotic inhibitors. Mitotic inhibitors are medications that stop cell division or mitosis. These medications disrupt microtubules which pull the chromosomes apart when a cell divides. These medications can disrupt the microtubules, which are responsible for dividing the chromosomes during cell divisions. These sectors include hospitals, clinics and others. They are available through a variety of channels, including ambulatory surgical centres, hospitals, clinics and retail pharmacies as well as online channels. Breast cancer can be caused by a wide range of factors.

These include lifestyle, age and heredity as well as genetic mutations (abnormalities). Scientists are currently studying how genes can affect breast cancer. They also study new imaging methods that allow for early detection of abnormalities. Breast cancer is the disease in which malignant cells grow uncontrollably in breast tissue. It affects more women than men. Uncontrolled cell division in breast cells is called breast cancer. It affects the most common cells of the breast lobules and ducts. Breast cancer symptoms include a lump in the breast, bleeding from the nipple, and changes in the shape or size of the breast. The stage of breast cancer will determine the treatment. The treatment of breast cancer includes chemotherapy, radiation, hormone therapy and surgery. All medical centers around the globe are concerned about the growth of the breast cancer drug market. They also want to focus their research on targeted therapies and improved chemotherapy drugs.

The breast cancer drug market is booming with bio-similar treatments, new generation treatments, and bio-similar versions. As it has been shown that vaccinations against cancer have higher success rates in killing tumor cells, innovative and progressive treatments are being developed. Some vaccines can be customized, while others are more general.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Breast Cancer Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Breast Cancer Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Roche
  • Novartis AG
  • AbbVie Inc.
  • AstraZeneca
  • Eli Lilly
  • Celgene Corporation
  • Biocon
  • MerckCo.
  • Genzyme Corporation
  • Janseen Global Services LLC
  • MacroGenics Inc.
  • Celldex Therapeutics
  • Onyx Pharmaceuticals Inc.
  • BioNumerik Pharmaceutical Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Type

  • HER2 inhibitors
  • Mitotic inhibitors
  • Anti-metabolites
  • Aromatase inhibitors
  • CDK 4/6 Inhibitors
  • Hormonal receptor

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Breast Cancer Drugs Market By Drug Type and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Breast Cancer Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Online Pharmacy Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Breast Cancer Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Breast Cancer Drugs Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. HER2 inhibitors
        2. Mitotic inhibitors
        3. Anti-metabolites
        4. Aromatase inhibitors
        5. CDK 4/6 Inhibitors
        6. Hormonal receptor

  • 8.   North America Breast Cancer Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 9.   Latin America Breast Cancer Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 10.   Europe Breast Cancer Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.7. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 11.   Asia Pacific Breast Cancer Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 12.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 13.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 14.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Roche
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Novartis AG
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. AbbVie Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. AstraZeneca
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Eli Lilly
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Celgene Corporation
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Biocon
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. MerckCo.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Genzyme Corporation
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Janseen Global Services LLC
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. MacroGenics Inc.
         11.1. Company Overview
            11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Celldex Therapeutics
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Onyx Pharmaceuticals Inc.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. BioNumerik Pharmaceutical Inc.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview

  • 15.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 16.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients